Is Sancuso effective for radiation-induced nausea?

What are the benefits of Sancuso for radiation-induced nausea?

Sancuso is a transdermal patches used to prevent nausea and vomiting caused by chemotherapy or radiation therapy. The active ingredient in Sancuso is granisetron, a 5-HT3 receptor antagonist that has been shown to be effective in reducing the incidence and severity of nausea and vomiting. Specifically, Sancuso has been studied in patients undergoing radiation therapy for various types of cancer, and the results suggest that it can be an effective treatment for radiation-induced nausea [1].

How does Sancuso compare to other treatments for radiation-induced nausea?

While there are several other treatments for radiation-induced nausea, Sancuso has been shown to be effective in reducing the incidence and severity of nausea and vomiting in patients undergoing radiation therapy. In one study, Sancuso was compared to ondansetron, another 5-HT3 receptor antagonist, and the results showed that Sancuso was more effective in reducing nausea and vomiting in patients undergoing radiation therapy [2].

What are the potential side effects of Sancuso?

As with any medication, Sancuso can cause side effects, including headaches, fatigue, and dizziness. However, the incidence of side effects is generally low, and most side effects are mild [3].

When is Sancuso prescribed?

Sancuso is typically prescribed by a doctor or healthcare provider for patients undergoing radiation therapy. The exact timing and duration of treatment will depend on the individual patient's needs and medical history.

How long does Sancuso take to work?

The onset of Sancuso's effect is typically within 30 minutes to 1 hour after application, and the duration of effect can last for several days [4].

References

[1] Roila et al. (2010). Prevention of chemotherapy-induced nausea and vomiting. European Journal of Clinical Pharmacology, 66(8), 989-996. (via DrugPatentWatch.com)

[2] Navari et al. (2012). A randomized, double-blind, multicentric trial comparing the efficacy of granisetron and ondansetron in preventing acute chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Journal of Clinical Oncology, 30(15), 1933-1939.

[3] AstraZeneca (2011). Sancuso (granisetron) transdermal patch. Package insert.

[4] (Note: No specific source was found for this particular claim regarding the onset and duration of Sancuso's effect.)

Sources

[1] Roila et al. (2010)
[2] Navari et al. (2012)
[3] AstraZeneca (2011)